Kolon Life Science TG-C Cartilage Regeneration Patent Registered in Indonesia

[Financial News] Kolon Life Science announced on the 26th that a patent for 'cartilage regeneration using chondrocytes and TGF-β' has been registered in Indonesia for the cell gene therapy 'TG-C (formerly Invossa)' being developed by its affiliate Kolon TissueGene. With this registration decision, Kolon Life Science has further strengthened its technological and commercial position in the local market by preparing legal protection measures based on the TG-C implementation rights and patent rights secured from Kolon TissueGene in Indonesia.
The patent includes a technical means of manufacturing transgenic cells by introducing 'TGF-β1' (a gene that promotes anti-inflammatory and cartilage component production) into human embryonic kidney-derived GP2-293 cells. Through this, it is expected to induce tissue and hyaline cartilage regeneration, thereby improving joint function and structure.
In particular, the transgenic GP2-293 cells have been completely cleared of tumorigenicity through irradiation and are designed to die off after expressing the TGF-β1 protein for a certain period. By applying a direct intra-articular injection method, systemic exposure is blocked, greatly enhancing safety.
This patent has been decided to be registered in five countries, including Indonesia, China, Japan, Australia, and the Philippines. Kolon Life Science holds the exclusive implementation rights for TG-C in these regions, allowing free production and sales of the product and the authority to restrict unauthorized use of the technology by third parties.
With this patent registration decision, Kolon Life Science has further strengthened its position by preparing legal protection measures based on the exclusive implementation rights and patent rights for TG-C in Indonesia.
According to the global market research firm Grand View Research, the osteoarthritis treatment market in the Asia-Pacific region is expected to grow at an average annual rate of 9.3% from 2025 to 2030, reaching approximately 3.3588 billion dollars (4.7 trillion won) by 2030.
Indonesia is one of the bio-medical markets with high growth potential in Southeast Asia, actively introducing advanced medical technology and building clinical infrastructure, and TG-C's local entry is expected to serve as a bridgehead for expanding into the Asian market in the future.
Kim Sun-jin, CEO of Kolon Life Science and Chief Medical Officer (CMO) of Kolon TissueGene, said, "This decision to register the patent in Indonesia is a result of the international recognition of TG-C's technology and safety," adding, "Based on this, we will further accelerate our entry into the global market, including Indonesia."

vrdw88@fnnews.com Kang Jung-mo Reporter